Scott Gottlieb, who recently stepped down as the head of the U.S. FDA, has rejoined venture capital firm New Enterprise Associates as a full-time investing partner. Gottlieb had been a venture partner with NEA for 10 years before President Trump tapped him to lead the FDA. He's expected to lead investments in life sciences startups and take board seats on behalf of the firm. Gottlieb also recently rejoined the American Enterprise Institute as a resident scholar, and he plans to maintain that position. Alert readers will recall that Mr. Gottlieb resigned abruptly from his leadership position at the FDA just months ago. Learn More

After a four-year decline that erased 65% from the value of Sun Pharma, comes word that the world's biggest generic drug manufacture will pursue branded drugs. That won't be easy, especially when the multinationals that dominate the pharmaceutical business have already seen the payoffs from their massive research and development spending become more uncertain. Those giants are increasingly turning to acquisitions to fill out their pipelines, and that's where Sun Pharma sees an opening. Sun Pharma thinks the company can eventually pick up enough early-stage innovations and key personnel to generate half its revenue from patented medicines. Learn More

Boehringer Ingelheim has announced a multi-million-dollar investment that will see the expansion of its manufacturing capacity in Mexico over the next two years. The majority of the investment, $52 million will be at the biopharma giants site in Xochimilco which specializes in oral dosage anti-diabetic drugs. The Xochimilco plant is one of three sites that Boehringer has in Mexico, and the capital injection will be destined to increase the production capacity by at least 50%. The expansion at the Xochimilco plant is part of an investment plan to invest $84 million by 2023 to boost production at all three of its production sites in the country. Learn More